FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

A systematic review and meta-analysis found some supporting evidence for transdermal anti-inflammatory patches, but the ...

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira ...

In November 2024, a regulatory advisory board said the benefits of Zynquista does not outweigh the risks in adults with type ...

Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits.

Take a look at this year’s top articles — one showcasing enhanced weight loss through Semaglutide use in post-menopausal ...

Here are the top performing articles about obesity published this year on Managed Healthcare Executive. 1. GLP-1 Tiering ...

Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...

This year’s top dermatology posts on Managed Healthcare Executive include stories about Gen Z sunscreen trends and increasing ...

Kamilia Smith, MD, FACOG, NCMP, discusses how educating patients about the serious long-term health risks of untreated vasomotor symptoms (VMS) requires a comprehensive strategy that includes clear ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...